BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38054837)

  • 21. Current management of newly diagnosed acute promyelocytic leukemia.
    Cicconi L; Lo-Coco F
    Ann Oncol; 2016 Aug; 27(8):1474-81. PubMed ID: 27084953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
    Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
    Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
    Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
    Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
    Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
    [No Abstract]   [Full Text] [Related]  

  • 26. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
    Wang QQ; Hua HY; Naranmandura H; Zhu HH
    Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
    Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
    Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
    Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Xu SN; Chen JP; Liu JP; Xia Y
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
    Zhang X; Wu S; Yang J; Zhang G; Su Y; Zhang M; He J; Shi Y; Li W; Lu P; Lu D
    Int J Hematol; 2023 Apr; 117(4):530-537. PubMed ID: 36580227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
    Wang HY; Zhang HY; Liu Y; Zhang XX; Gong S; Chen LM; Wang MC; Xi JY; Liu X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):705-709. PubMed ID: 29950207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation syndrome in acute promyelocytic leukaemia.
    Stahl M; Tallman MS
    Br J Haematol; 2019 Oct; 187(2):157-162. PubMed ID: 31410848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.
    Collinge E; Tigaud I; Balme B; Gerland LM; Sujobert P; Carlioz V; Salles G; Thomas X; Paubelle E
    Medicine (Baltimore); 2018 Feb; 97(8):e9657. PubMed ID: 29465554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
    Korístek Z; Zák P
    Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
    Mannis GN; Logan AC; Leavitt AD; Yanada M; Hwang J; Olin RL; Damon LE; Andreadis C; Ai WZ; Gaensler KM; Greene CC; Gupta NK; Kaplan LD; Mahindra A; Miyazaki Y; Naoe T; Ohtake S; Sayre PH; Smith CC; Venstrom JM; Wolf JL; Caballero L; Emi N; Martin TG
    Bone Marrow Transplant; 2015 Jan; 50(1):40-4. PubMed ID: 25243620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome of acute promyelocytic leukemia treated with all-
    Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
    Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.